Virtual Library

Start Your Search

H.R. Kim



Author of

  • +

    P1.06 - Poster Session with Presenters Present (ID 458)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P1.06-036 - Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment (ID 5805)

      14:30 - 15:45  |  Author(s): H.R. Kim

      • Abstract
      • Slides

      Background:
      The aim of this retrospective study was to review recurrence patterns of stage I non-small cell lung cancer(NSCLC), and to identify prognostic factors for post-recurrence survival(PRS).

      Methods:
      Among 940 patients with pathological stage I NSCLC who had undergone curative resection between 2001 and 2009, total 261 patients who had experienced recurrence were included in this study. Number of patients with adenocarcinoma(ADC) were 188, squamous cell carcinoma(SCC) were 62. Oligo-recurrence was defined as 1-3 loco-regional or distant recurrent lesions restricted to a single organ. Potentially-curative local treatment(PCLT) included surgery, stereotactic radiotherapy(SRT), and photodynamic therapy(PDT).

      Results:
      Median follow-up duration was 65 months(range, 4-186 months) and median disease-free interval(DFI) was 23 months(range, 2-95 months). Number of patients with oligo-recurrence was 154, and the most common sites of oligo-recurrence were lung in 84 patients, followed by brain in 18 patients, bronchial stump in 18, and single-station of mediastinal lymph nodes in 12. Local treatment for recurrent tumor included surgery in 59 patients, SRT in 50, PDT in 2, and other radiotherapy in 53. Seventy-four patients received chemotherapy only, and 36 patients took conservative treatment. Among 125 patients who were evaluated for EGFR gene mutation study, positive results was detected in 62 patients, and 31 patients were treated with TKI. The 3- and 5-year post-recurrence survival rates were 49.1% and 33.8%, respectively. Age at recurrence, adenocarcinoma cell-type, DFI, TKI and PCLT were independent prognostic factors in multivariate analysis. Figure 1



      Conclusion:
      Local treatment of oligo-recurrence should be considered in selected candidates, and use of TKI is reasonable if EGFR mutation is detected.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.